A checkpoint inhibitor gains FDA approval in endometrial cancer
On April 22, 2021, the US Food and Drug Administration (FDA) granted Accelerated Approval to dostarlimab (Jemperli, GlaxoSmithKline) as...
Recent developments in primary hyperoxaluria treatment
Primary hyperoxaluria (PH) is a rare genetic disease in which high levels of oxalate are produced and can deposit...
Cancer vaccines in the clinic and in trials
Most vaccines are given as prophylactics, agents that protect healthy individuals before exposure to a pathogen. By contrast, therapeutic...
FDA Approves First Trial of CRISPR for Sickle Cell Disease
The U.S Food and Drug Administration (FDA) has approved the first clinical trial of CRISPR to correct sickle cell...
Exon-skipping drug approved for the third subtype of Duchenne muscular dystrophy
Discovering treatments for Duchenne muscular dystrophy has been difficult because the disease is a result of a wide variety...
CAR-T Therapy Approved for B-Cell Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma treatment traditionally relied on chemotherapy, radiation, and bone marrow transplant. More recently, immuno-oncology treatments have come to...
Bispecific antibodies are progressing in cancer clinical trials
The human immune system makes antibodies that bind to the same antigen with both of their variable regions, or...
A new device for mild sleep apnea
Most non-surgical options for managing mild sleep apnea simply keep the airway open while the individual sleeps. A new...
CRISPR-Based Diagnostics on the Rise
In 2020, the Nobel Prize in Chemistry was awarded for “the development of a method for genome editing” based...
Phase III trial beginning for a Charcot-Marie-Tooth disease therapy
An investigational therapy for Charcot-Marie-Tooth (CMT) disease is beginning its second Phase III trial. The therapy, called PXT3003, is...